Ailin Bai

This inventor holds 28 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Modernatx, Inc., Aveo Pharmaceuticals, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ailin Bai. Retrieved from https://idiyas.com/inventor/ailin-bai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 8)

% Patents Active = 96.4

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 5.0

ph-index = 7

Forward Citations = 124(Granted Patents)

Location History:

Newton, MA (US) (2013 - 2023)
Cambridge, MA (US) (2023)

Company Filing History:

Aveo Pharmaceuticals, Inc.

patents

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Anti-GDF-15 Antibodies

mRNA Combination Therapy

OX40 Ligand

Polynucleotides

Immune Modulating Polypeptides

Interleukin-12

Cancer Treatment

Therapeutic Methods

Antibodies

Immunotherapy

Polynucleotide Encoding

Cancer Research

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258391 - Anti-GDF-15 antibodies (2025-03-25),

2. 11725047 - Anti-GDF-15 antibodies (2023-08-15),

3. 11687256 - Methods of using OX40 ligand encoding polynucleotides (2023-06-27),

4. 11660341 - mRNA combination therapy for the treatment of cancer (2023-05-30),

5. 11596609 - Combinations of mRNAs encoding immune modulating polypeptides and uses thereof (2023-03-07),

6. 11571463 - Polynucleotides encoding interleukin-12 (IL12) and uses thereof (2023-02-07),

7. 11403008 - Methods of using OX40 ligand encoding polynucleotides (2022-08-02),

8. 11344504 - Combinations of mRNAs encoding immune modulating polypeptides and uses thereof (2022-05-31),

9. 11311602 - Polynucleotides encoding interleukin-12 (IL12) and uses thereof (2022-04-26),

10. 11185510 - Combinations of mRNAs encoding immune modulating polypeptides and uses thereof (2021-11-30),

11. 11071716 - Combinations of mRNAs encoding immune modulating polypeptides and uses thereof (2021-07-27),

12. 11003366 - Methods of using OX40 ligand encoding polynucleotides (2021-05-11),

13. 11000573 - Polynucleotides encoding interleukin-12 (IL12) and uses thereof (2021-05-11),

14. 10973917 - MRNA combination therapy for the treatment of cancer (2021-04-13),

15. 10646549 - Polynucleotides encoding interleukin-12 (IL12) and uses thereof (2020-05-12),

Title: The Innovative Contributions of Ailin Bai in Biomedicine

Introduction

Ailin Bai, based in Newton, MA, is a prolific inventor and innovator in the field of biomedicine, holding an impressive portfolio of 27 patents. His work primarily focuses on developing therapeutic agents that address critical health issues, showcasing his dedication to advancing medical science and improving patient outcomes.

Latest Patents

Among Ailin Bai's latest inventions is the development of anti-GDF-15 antibodies. These monoclonal antibodies are designed to bind and inhibit the activity of human GDF15, potentially offering treatment options for body weight loss, including cachexia, related to the over-expression of this protein. Additionally, he has contributed to methods of using OX40 ligand encoding polynucleotides, which encompasses the preparation and therapeutic applications of polynucleotide molecules that encode OX40L polypeptides. This innovation includes techniques for activating T cells and increasing the number of natural killer (NK) cells, aiming to enhance immune responses in patients.

Career Highlights

Ailin Bai has made significant strides in the biotechnology sector, having worked with notable organizations such as Moderna, Inc. and Aveo Pharmaceuticals, Inc. His role in these companies has facilitated advancements in therapeutic development and patient care through his innovative contributions.

Collaborations

Throughout his career, Ailin Bai has collaborated with other talented individuals, including Joshua P. Frederick and Vladimir Presnyak. These partnerships have likely enriched his research endeavors, promoting a collaborative approach to tackling complex biomedical challenges.

Conclusion

Ailin Bai's innovative spirit and commitment to biomedicine have resulted in a robust patent portfolio that underscores his impact in the field. His ongoing research and collaborations continue to hold promise for future medical advancements, exemplifying the role of inventors in creating solutions for pressing health issues.

Profile summary based on public USPTO records.